Acquisitions, Collaboration, License and Other Strategic Agreements (Details) $ in Thousands			1 Months Ended		3 Months Ended		6 Months Ended
	May 21, 2020 USD ($) day	Jan. 16, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jan. 31, 2017 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gain on sale of assets					$ 14,444	$ 0	$ 14,444	$ 0
Velo Bio, LLC | Regulatory Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments			$ 5,000
Velo Bio, LLC | Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments			30,000
Velo Bio, LLC | Annual Sales Milestone Achievements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments			240,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone targets			300,000
Velo Bio, LLC | Annual Sales Milestone Achievements | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales milestone targets			900,000
Velo Bio, LLC | Commercial Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments			$ 10,000
Intrarosa | Millicent Pharma Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds related to collaborative arrangement	$ 20,900
Gain on sale of assets					$ 14,400		14,400
Intrarosa | Millicent Pharma Limited | Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Transaction Fees
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative arrangement							2,500
Intrarosa | Millicent Pharma Limited | Collaborative Arrangement, Transaction With Party To Collaborative Arrangement, Carrying Value Of Assets Sold And Other Costs
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments related to collaborative arrangement							$ 4,000
Intrarosa | Millicent Pharma Limited | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement	105,000
Intrarosa | Millicent Pharma Limited | First Time Net Sales During Threshold Period Exceeds $65 Million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement	25,000
Potential milestone proceeds, triggering event, sales	$ 65,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in days) | day	12
Intrarosa | Millicent Pharma Limited | First Time Net Sales During Threshold Period Exceeds $115 Million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement	$ 35,000
Potential milestone proceeds, triggering event, sales	$ 115,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in days) | day	12
Intrarosa | Millicent Pharma Limited | First Time Net Sales During Threshold Period Exceeds $175 Million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone proceeds from collaborative arrangement	$ 45,000
Potential milestone proceeds, triggering event, sales	$ 175,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in days) | day	12
Vyleesi Products | Palatin Technologies, Inc. | First Sales Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential milestone payment, triggering event, sales				$ 250,000
Future contingent payments (up to)				25,000
Vyleesi Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones over Course of License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future contingent payments (up to)				$ 300,000
Perosphere Pharmaceuticals Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)		$ 365,000
Perosphere Pharmaceuticals Inc. | Regulatory Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)		$ 140,000
Credited percentage		50.00%
Perosphere Pharmaceuticals Inc. | Milestone Achievement, Approval by European Medicines Agency
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)		$ 40,000
Perosphere Pharmaceuticals Inc. | Sales Milestones Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration (up to)		225,000
Perosphere Pharmaceuticals Inc. | First Sales Milestone Achievement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent consideration, milestone payment		20,000
Potential milestone payment, triggering event, sales		$ 100,000